文献速递其他结缔组织病

MRI指动脉体积指数(DAVIX)作为系统性硬化症患者指端溃疡疾病的替代结局指标:一项前瞻性队列研究

MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2023-09-25

在两项独立前瞻性队列中评估MRI指标DAVIX与系统性硬化症指端溃疡的关联。探索队列85例和验证队列150例中,有指端溃疡者DAVIX均显著低于无溃疡者,且DAVIX较低者12个月内新发溃疡更多。DAVIX与疾病持续时间、甲襞毛细血管镜模式等呈负相关,作者认为其是有前景的替代结局指标。

要点

  • 有指端溃疡者DAVIX显著低于无溃疡者,探索队列0.34% vs 0.65%,验证队列0.43% vs 0.73%。
  • 12个月内新发指端溃疡者基线DAVIX更低(0.23% vs 0.65%,p=0.0039)。
  • DAVIX与疾病持续时间、甲襞毛细血管镜模式、改良Rodnan皮肤评分呈负相关。

核心结论

  • DAVIX是系统性硬化症指端溃疡疾病有前景的替代结局指标。
  • DAVIX可无创预测未来指端溃疡和患者报告结局恶化,可能有助于临床试验中的患者富集和分层。
  • 临床上DAVIX可能为血管活动度评估提供信息,其随时间及治疗变化的敏感性将确定其作为血管疾病影像学结局指标的价值。

研究设计与样本

  • 前瞻性观察研究STRIKE的两项独立队列,连续纳入来自英国利兹教学医院信托硬皮病门诊的患者。
  • 纳入标准为年龄18岁及以上且符合VEDOSS或2013年ACR-EULAR系统性硬化症分类标准。
  • DAVIX计算为优势手四指指动脉体积与手指体积比值的百分比均值,基线和12个月随访时收集数据,主要结局为12个月随访时指端溃疡的存在。
  • 探索队列85例,验证队列150例,纳入时间为2018年2月7日至2022年4月11日。

主要发现

  • 探索队列中,既往或活动性指端溃疡患者DAVIX为0.34%(IQR 0.16-0.69),无指端溃疡疾病者为0.65%(0.42-0.88),p=0.015。
  • 验证队列中,既往或活动性指端溃疡患者DAVIX为0.43%(0.20-0.73),无指端溃疡疾病者为0.73%(0.53-0.97),p<0.0001。
  • 12个月随访期间新发指端溃疡者DAVIX为0.23%(0.10-0.66),未新发者为0.65%(0.45-0.91),p=0.0039。
  • DAVIX与疾病持续时间(r=-0.415;p<0.0001)、用力肺活量与一氧化碳弥散量比值(r=-0.334;p=0.0091)、甲襞毛细血管镜模式(r=-0.447;p<0.0001)及基线改良Rodnan皮肤评分(r=-0.305;p=0.014)呈负相关,与一氧化碳弥散量呈正相关(r=0.368;p=0.0041)。
  • DAVIX与硬皮病健康评估问卷-残疾指数评分变化(r=-0.308;p=0.024)、雷诺现象视觉模拟量表(r=-0.271;p=0.044)及指端溃疡视觉模拟量表(r=-0.291;p=0.044)呈负相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular fibrosis is a key manifestation of systemic sclerosis that leads to the narrowing of small and medium arteries, causing vascular clinical manifestations including digital ulcers and pulmonary arterial hypertension. We investigated the potential of the MRI-based Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of vascular fibrosis by using it to quantify and predict the burden of digital ulcer disease in patients with systemic sclerosis. METHODS: Two independent cohorts of patients participating in the prospective observational study STRIKE were consecutively enrolled from the Scleroderma Clinic of the Leeds Teaching Hospitals Trust, Leeds, UK. Eligible patients were aged 18 years or older and fulfilled the very early diagnosis of systemic sclerosis (VEDOSS) or the 2013 American College of Rheumatology (ACR)-European Alliance of Associations for Rheumatology (EULAR) systemic sclerosis classification criteria. DAVIX was calculated as the percentage mean of the ratio of digital artery volume to finger volume in the four fingers of the dominant hand. Data were collected at baseline and 12-month follow-up, and the primary outcome was the presence of digital ulcers at 12-month follow-up. FINDINGS: Between Feb 7, 2018, and April 11, 2022, we included 85 patients in the exploratory cohort and 150 in the validation cohort. In the exploratory cohort, the mean age was 54·5 years (SD 11·6), 75 (88%) of 85 patients were women, ten (12%) were men, and 69 (82%) were White. In the validation cohort, the mean age was 53·5 years (SD 13·8), 136 (91%) of 150 patients were women, 14 (9%) were men, and 127 (85%) were White. In the exploratory cohort, DAVIX was significantly lower in patients with previous or active digital ulcers (0·34% [IQR 0·16-0·69]) than in those without digital ulcer disease (0·65% [0·42-0·88]; p=0·015); this finding was substantiated in the validation cohort (0·43% [0·20-0·73] vs 0·73% [0·53-0·97]; p<0·0001). Patients who developed new digital ulcers during 12-month follow-up had a lower DAVIX (0·23% [0·10-0·66]) than those who did not (0·65% [0·45-0·91]; p=0·0039). DAVIX was negatively correlated with disease duration (r=-0·415; p<0·0001), the ratio of forced vital capacity to the diffusing capacity of the lungs for carbon monoxide (r=-0·334; p=0·0091), nailfold capillaroscopy pattern (r=-0·447; p<0·0001), and baseline modified Rodnan skin score (r=-0·305; p=0·014) and was positively correlated with the diffusing capacity of carbon monoxide (r=0·368; p=0·0041). DAVIX was negatively correlated with change in score on the Scleroderma Health Assessment Questionnaire-Disability Index (r=-0·308; p=0·024), Visual Analogue Scale (VAS) Raynaud's (r=-0·271; p=0·044), and VAS digital ulcers (r=-0·291; p=0·044). INTERPRETATION: DAVIX is a promising surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis. The ability of DAVIX to non-invasively predict future digital ulcers and worsening of patient-reported outcomes could aid patient enrichment and stratification in clinical trials. Clinically, DAVIX could offer insights into the assessment of vascular activity. The sensitivity of DAVIX to change over time and with treatment will establish its value as an imaging outcome measure of vascular disease. FUNDING: National Institute for Health Research Biomedical Research Centre and University of Leeds Industry Engagement Accelerator Fund.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hughes M, Di Donato S, Gjeloshi K, et al. MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study. Lancet Rheumatol. 2023. PMID: 38251485. doi:10.1016/S2665-9913(23)00189-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。